Latest News
Oct 8, 2018
ReViral at 11th International Respiratory Syncytial Virus Symposium

ReViral's CEO, Dr Eddy Littler, and Head of Virology, Dr Elaine Thomas, will be presenting "Low rate of resistance to the RSV fusion inhibitor RV521 in human infection" at the 11th International Respiratory...

Oct 8, 2018
ReViral to present at RespiDART 2018

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at RespiDART 2018 in Miami on 29th November 2018. The afternoon session entitled "Therapeutics against respiratory viruses: Clinical advances...

Oct 8, 2018
ReViral at 6th ISIRV AVG Conference

ReViral's Chief Operating Officer, Dr Rachel Harland, will be presenting the poster "Efficacy of the RSV fusion Inhibitor RV521 in human infection" at The 6th ISIRV AVG Conference in Washington DC, USA (13th - 15th...

Aug 1, 2018
ReViral announces Series B investment

ReViral announces US$55 million series B fundraising to advance RSV clinical studies

London, UK – 1st August 2018:  ReViral, an antiviral drug discovery and development company,...

May 14, 2018
Presentation at the American Thoracic Society

ReViral is pleased to announce that Professor John DeVincenzo from the Department of Pediatrics, University of Tennessee, Memphis, USA will be presenting at the American Thoracic Society in San Diego. The...

Mar 20, 2018
ReViral to present at American Chemical Society

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at the American Chemical Society in New Orleans. The afternoon session entitled "MEDI: First Time Disclosures of Clinical Candidates" begins...

Feb 5, 2018
Positive results achieved in ReViral’s Phase IIa RSV challenge study

ReViral’s RV521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms

London, UK, 5th February 2018 / ReViral, a UK-based biotech...

Archived News
Nov 2, 2017
ReViral present Phase 2a update at BIO-Europe
Sep 5, 2017
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus
Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
Oct 3, 2016
ReViral Announces Appointment of New Chief Executive Officer
Sep 8, 2015
ReViral announces US$21 million fundraising to advance clinical development of a novel anti-viral drug
Upcoming Events
11th International Respiratory Syncytial Virus Symposium
Oct 31, 2018 to Nov 4, 2018
Asheville, NC, USA
More Information
24th Annual BioEurope Partnering Conference
Nov 5, 2018 to Nov 7, 2018
Copenhagen
More Information
The 6th ISIRV AVG Conference
Nov 13, 2018 to Nov 15, 2018
Washington
More Information
RespiDART 2018
Nov 29, 2018 to Nov 30, 2018
Miami
More Information
Genesis 2018
Dec 13, 2018
J.P. Morgan 37th Annual Healthcare Conference
Jan 7, 2019 to Jan 10, 2019
San Francisco
More Information
Past Events
10th Annual Biotech Showcase
Jan 8, 2018 to Jan 11, 2018
San Francisco
More Information
255th ACS National Meeting & Exposition
Mar 18, 2018 to Mar 22, 2018
Ernest N. Morial Convention Center, New Orleans, LA
More Information
American Thoracic Society Conference 2018
May 18, 2018 to May 23, 2018
San Diego, CA
More Information